Undifferentiated pleomorphic sarcoma, inflammatory variant

Summary

Undifferentiated pleomorphic sarcoma, inflammatory variant (MONDO:0006480) is a cancer and 1 clinical trial. Top therapeutic interventions include nivolumab. A subtype of undifferentiated pleomorphic sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	undifferentiated pleomorphic sarcoma, inflammatory variant
Mondo ID	MONDO:0006480
EFO	EFO:1000608
DOID	DOID:6192
NCIT	C6497
UMLS	C1334180
MedGen	235211
GARD	0024429
Is cancer (heuristic)	yes

Also known as: inflammatory malignant fibrous histiocytoma · inflammatory MFH · malignant xanthogranuloma · undifferentiated pleomorphic sarcoma, inflammatory variant

Disease family

This is a subtype of undifferentiated pleomorphic sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › histiocytoma › undifferentiated pleomorphic sarcoma › undifferentiated pleomorphic sarcoma, inflammatory variant

Related subtypes (2): cutaneous undifferentiated pleomorphic sarcoma, malignant giant cell tumor of soft parts

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04420975	PHASE1	ACTIVE_NOT_RECRUITING	Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NIVOLUMAB	4	1